AbbVie Inc. $ABBV Stock: BDF Gestion Trims Position

BDF Gestion lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 11.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,503 shares of the company’s stock after selling 4,503 shares during the period. AbbVie makes up 1.3% of BDF Gestion’s investment portfolio, making the stock its 13th largest position. BDF Gestion’s holdings in AbbVie were worth $9,287,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ABBV. Foguth Wealth Management LLC. grew its stake in shares of AbbVie by 18.0% in the third quarter. Foguth Wealth Management LLC. now owns 1,714 shares of the company’s stock valued at $489,000 after buying an additional 262 shares in the last quarter. Prospera Capital Management LLC acquired a new position in AbbVie in the 3rd quarter valued at about $362,000. Optivise Advisory Services LLC increased its stake in AbbVie by 5.2% during the third quarter. Optivise Advisory Services LLC now owns 2,847 shares of the company’s stock worth $745,000 after purchasing an additional 141 shares during the period. Narus Financial Partners LLC increased its stake in AbbVie by 24.9% during the third quarter. Narus Financial Partners LLC now owns 2,983 shares of the company’s stock worth $780,000 after purchasing an additional 595 shares during the period. Finally, Clark Wealth Partners boosted its stake in shares of AbbVie by 1.3% in the third quarter. Clark Wealth Partners now owns 4,110 shares of the company’s stock valued at $1,075,000 after purchasing an additional 54 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Down 0.5%

AbbVie stock traded down $1.50 during trading on Monday, reaching $283.92. The stock had a trading volume of 1,337,542 shares, compared to its average volume of 6,387,841. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40. The stock has a market cap of $501.63 billion, a PE ratio of 80.21, a P/E/G ratio of 1.30 and a beta of 0.24. The business has a 50 day moving average price of $262.74 and a 200 day moving average price of $239.41.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm posted $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ABBV has been the topic of several recent research reports. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $280.00 price objective on shares of AbbVie in a research report on Tuesday, October 13th. Leerink Partners lifted their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. HSBC boosted their target price on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Canaccord Genuity Group upped their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.